<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Nadolol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01203</strong>&#160; (APRD00301)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01203/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01203/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01203.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01203.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01203.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01203.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01203.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01203">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Anabet</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Corgard</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Solgol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Corzide Tab W Nadolol 40mg</td><td>Bendroflumethiazide + Nadolol</td></tr><tr><td>Corzide Tab W Nadolol 80mg</td><td>Bendroflumethiazide + Nadolol</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>42200-33-9</td></tr><tr><th>Weight</th><td>Average: 309.4006<br>Monoisotopic: 309.194008357</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>27</sub>NO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>VWPOSFSPZNDTMJ-UCWKZMIHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Tetralins</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Tetralins</td></tr><tr><th>Alternative parents</th><td>Phenol Ethers; Alkyl Aryl Ethers; 1,2-Diols; Secondary Alcohols; 1,2-Aminoalcohols; Polyamines; Dialkylamines</td></tr><tr><th>Substituents</th><td>phenol ether; alkyl aryl ether; benzene; 1,2-aminoalcohol; secondary alcohol; 1,2-diol; secondary amine; polyamine; secondary aliphatic amine; ether; alcohol; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension.</td></tr><tr><th>Pharmacodynamics</th><td>Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.</td></tr><tr><th>Mechanism of action</th><td>Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.</td></tr><tr><th>Absorption</th><td>Absorption of nadolol after oral dosing is variable, averaging about 30 percent.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>30%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Not metabolized by the liver and excreted unchanged primarily by the kidneys.</p></td></tr><tr><th>Route of elimination</th><td>Unlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the liver and is excreted unchanged, principally by the kidneys.  Nadolol is excreted predominantly in the urine.</td></tr><tr><th>Half life</th><td>14-24 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Nadolol Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9788</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.966</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8317</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.6192</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7842</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8736</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7934</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.7284</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5456</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8308</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8072</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8934
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.7972 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9455
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5781
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>King pharmaceuticals inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mylan pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.apothecon.nl">Apothecon</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>E.R. Squibb and Sons LLC</li>
<li><a href="http://www.emcure.co.in">Emcure Pharmaceuticals Ltd.</a></li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li><a href="http://www.impaxlabs.com">Impax Laboratories Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.kingpharm.com">King Pharmaceuticals Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.meadjohnson.com">Mead Johnson and Co.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Professional Co.</li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li>Quality Care</li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00414">Acetohexamide</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00575">Clonidine</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Ischemia with risk of gangrene.</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>The beta-blocker, nadolol, may increase the toxicity of disopyramide.</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>Hypertension, then bradycardia</td></tr><tr><td><a href="/drugs/DB01253">Ergonovine</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01288">Fenoterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00983">Formoterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01120">Gliclazide</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01067">Glipizide</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01289">Glisoxepide</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01382">Glycodiazine</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00047">Insulin Glargine</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01064">Isoprenaline</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00281">Lidocaine</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00968">Methyldopa</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00247">Methysergide</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00816">Orciprenaline</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00236">Pipobroman</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01291">Pirbuterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00457">Prazosin</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB01366">Procaterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00912">Repaglinide</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01001">Salbutamol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00938">Salmeterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01162">Terazosin</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00871">Terbutaline</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00839">Tolazamide</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Increased effect of both drugs</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid natural licorice.</li>
<li>Magnesium, potassium and zinc needs increased.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>